Search clinical trials for: GT90001 and Nivolumab

Total 271495 results

AIO-Studien-gGmbH
Bristol-Myers Squibb

Completed

Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma (TITAN-RCC)

Carcinoma, Renal Cell | Clear-cell Metastatic Renal Cell Carcinoma

Spain, France, Italy, Germany, United Kingdom, Belgium, Czechia, Austria
National Cancer Institute (NCI)

Active, not recruiting

A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)

Metastatic Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Unresectable Renal Cell Carcinoma | TFE3-Rearranged Renal Cell Carcinoma

United States, Puerto Rico
The Netherlands Cancer Institute
Bristol-Myers Squibb

Completed

Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma (INITIATE)

Malignant Pleural Mesothelioma

Netherlands
China Medical University Hospital

Recruiting

Alectinib in Combination With Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided With Serum RNase1 and Tumor Expression of PD-L1

Hepatocellular Carcinoma

Taiwan
NYU Langone Health

Terminated

A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

Melanoma

United States
Fujian Medical University

Active, not recruiting

The Safety and Efficacy of Neoadjuvant Immunochemotherapy Followed by Laparoscopic Gastrectomy for Gastric Cancer

Locally Advanced Gastric Cancer

China
Bayer
Bristol-Myers Squibb

Completed

Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)

Colorectal Cancer

United States
Chinese PLA General Hospital

Not yet recruiting

Nivolumab, S-1 Combined With Oxaliplatin Versus Nivolumab as Neoadjuvant Therapy in Advanced Gastric Cancer

Gastric Cancer | Chemotherapy Effect
The Netherlands Cancer Institute
Bristol-Myers Squibb

Active, not recruiting

Checkpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UC (Indi-Blade)

Bladder Cancer | Urothelial Carcinoma

Netherlands
Bristol-Myers Squibb

Completed

A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection (CheckMate-6GE)

Melanoma

United States, Australia, Belgium, Italy, Poland, Spain, United Kingdom
Bristol-Myers Squibb

Withdrawn

A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer

Melanoma | Urothelial Carcinoma

Germany, Spain
Bristol-Myers Squibb

No longer available

Expanded Access for Fixed-Dose Combination of Nivolumab Plus Relatlimab
Presage Biosciences
Bristol-Myers Squibb; Celgene

Terminated

Intratumoral Microdosing of Motolimod in HNSCC

HNSCC

United States
Taiho Oncology, Inc.

Completed

A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC

Refractory Metastatic Colorectal Cancer

United States
Institut Claudius Regaud

Terminated

Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA)

Melanoma

France
Celleron Therapeutics Ltd.

Unknown

A Trial of CXD101 in Combination With Nivolumab in Patients With Metastatic Microsatellite-Stable Colorectal Cancer (CAROSELL)

Colorectal Neoplasms Malignant

United Kingdom
Memorial Sloan Kettering Cancer Center
IO Biotech

Recruiting

A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma

Melanoma

United States
Asan Medical Center

Not yet recruiting

FMT With Nivolumab in Patients With Advanced Solid Cancers Who Have Progressed During Anti-PD-(L)1 Therapy

Solid Carcinoma
Swiss Group for Clinical Cancer Research

Active, not recruiting

Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma

Renal Cell Carcinoma

Switzerland
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb; UConn Health; Adaptive Biotechnologies; MedGenome

Completed

Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)

Melanoma | Bladder Cancer

United States
Bayer
Bristol Myers Squibb Co. and Ono Pharmaceutical Co., Ltd

Active, not recruiting

A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors

Solid Tumors

United States, United Kingdom, Belgium, France, Taiwan, Japan, Italy, Korea, Republic of
Institut Curie
Bristol-Myers Squibb

Completed

Nivolumab in Association With Radiotherapy and Cisplatin in Locally Advanced Cervical Cancers Followed by Adjuvant Nivolumab for up to 6 Months (NiCOL)

Cervical Cancer | Locally Advanced Cervical Cancer

France
European Organisation for Research and Treatment...

Active, not recruiting

Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib (EBIN)

Stage IV Melanoma | Unresectable Stage III Melanoma

France, Denmark, Spain, Finland, Italy, Germany, Poland, United Kingdom, Netherlands
Nektar Therapeutics

Terminated

A Study of NKTR-262 in Combination With Bempegaldesleukin (NKTR-214) and With Bempegaldesleukin Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies (REVEAL)

Melanoma | Sarcoma | Renal Cell Carcinoma | Colorectal Cancer | Triple Negative Breast Cancer | Head and Neck Squamous Cell Carcinoma | Merkel Cell Carcinoma

United States
Taipei Medical University WanFang Hospital

Completed

Immune Profile and Prognosis of Malignant Liver Tumors With Radiofrequency Ablation (RFA) Therapy (RFA)

Liver Cancer

Taiwan
Nantes University Hospital
Bristol-Myers Squibb

Recruiting

Combined Therapy of Nivolumab and Adoptive T Cell Therapy in Metastatic Melanoma Patients (Nivo-TIL)

Melanoma

France
Memorial Sloan Kettering Cancer Center

Active, not recruiting

A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma

Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Unclassified Renal Cell Carcinoma | Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma | Fumarate Hydratase Deficient Renal Cell Carcinoma | Succinate Dehydrogenase Deficient Renal Cell Carcinoma | Collecting Duct Renal...

United States
Robert L. Ferris, MD, PhD
Bristol-Myers Squibb

Active, not recruiting

Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer

Oropharynx Squamous Cell Carcinoma | Carcinoma, Squamous Cell of Head and Neck

United States
Daiichi Sankyo, Inc.
Bristol-Myers Squibb

Terminated

Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal Cancer

Colorectal Neoplasm

United States
Sheba Medical Center
Prof. Ronit Satchi-Fainaro, Director, Cancer Biology Research Center, Tel...

Recruiting

Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases (14)

Advanced Glioblastoma | MGMT-Unmethylated Glioblastoma | Metastatic Melanoma in the Central Nervous System

Israel
Assistance Publique - Hôpitaux de Paris

Recruiting

Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence (CAPTiRALL)

Acute Lymphoblastic Leukemia, in Relapse | B Acute Lymphoblastic Leukemia

France
Tempest Therapeutics

Completed

TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers

Sarcoma | Renal Cell Carcinoma | Hepatocellular Carcinoma | Colorectal Cancer | Pancreatic Cancer | Squamous Cell Carcinoma of Head and Neck | Cholangiocarcinoma | Non-small Cell Lung Cancer | Urothelial Carcinoma | GastroEsophageal Cancer | Triple-Negative Breast Cancer | Metastatic Castration Resistant Prostate...

United States
National Cancer Institute (NCI)

Completed

Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma

Acute Adult T-Cell Leukemia/Lymphoma | Adult T-Cell Leukemia/Lymphoma | Chronic Adult T-Cell Leukemia/Lymphoma | HTLV-1 Infection | Lymphomatous Adult T-Cell Leukemia/Lymphoma | Smoldering Adult T-Cell Leukemia/Lymphoma

United States
National University Hospital, Singapore

Recruiting

A Phase I Dose Escalation Study of Selinexor Plus Nivolumab and Ipilimumab in Advanced/Metastatic Solid Malignancies

Metastatic Solid Malignancies | Advance Solid Malignancies

Singapore
Centre Leon Berard

Recruiting

Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype (RAR-Immune)

Sarcoma

France
Jason J. Luke, MD
Bristol-Myers Squibb; Agios Pharmaceuticals, Inc.

Completed

Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors

Glioma | Advanced Solid Tumor | IDH1 Mutation

United States
Bristol-Myers Squibb

Recruiting

A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma (RELATIVITY-127)

Melanoma

United States, Canada, Switzerland, Italy, Spain, Australia, France, Belgium, Finland, Israel, Germany, Sweden, Argentina, Brazil, Colombia, Mexico, Norway, Chile, United Kingdom, Austria, Poland, Czechia
Gritstone bio, Inc.
Bristol-Myers Squibb

Completed

A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens

Colorectal Cancer | Pancreatic Cancer | Non-Small Cell Lung Cancer | Solid Tumor | Shared Neoantigen-Positive Solid Tumors

United States
Fujian Cancer Hospital

Withdrawn

Study of FMT Combined With Nivolumab in Gastric Cancer

Gastric Adenocarcinoma | Esophagus Adenocarcinoma | Esophagogastric Junction Adenocarcinoma

China
St. Petersburg State Pavlov Medical University

Completed

Treatment With Nivolumab at the Fixed Dose 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkins Lymphoma (Nivo40)

Hodgkin Lymphoma

Russian Federation
TaiRx, Inc.

Recruiting

CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma | Advanced Cancer

Taiwan
YULISU
Ono Pharmaceutical Co. Ltd

Recruiting

Neoadjuvant Nivolumab for Upper Tract Urothelial Carcinoma

Upper Urinary Tract Urothelial Carcinoma

Taiwan
Astellas Pharma Global Development, Inc.
Merck Sharp & Dohme LLC

Completed

A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

United States, Korea, Republic of, Taiwan, Canada, Italy, Japan, Portugal, Spain, United Kingdom
Stichting Hemato-Oncologie voor Volwassenen Nederland

Active, not recruiting

DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL (HO152)

Lymphoma, B-Cell | Non Hodgkin Lymphoma | High-grade B-cell Lymphoma | MYC Translocation | BCL-2 Translocation

Netherlands, Belgium
Bristol-Myers Squibb

Active, not recruiting

A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery (CheckMate73L)

Non-Small Cell Lung Cancer (NSCLC)

Russian Federation, United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, China, France, Germany, Greece, Ireland, Italy, Japan, Korea, Republic of, Mexico, Netherlands, Poland, Puerto Rico, Romania, Spain, Sweden, Swit... and more
Bristol-Myers Squibb

Recruiting

An Observational Study to Evaluate Neoadjuvant Nivolumab (OPDIVO®) in Combination With Platinum-Based Chemotherapy in Non-Metastatic Non-Small Cell Lung Cancer Participants in Germany (NENI)

Resectable Non-small Cell Lung Cancer

Germany
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb

Active, not recruiting

Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma

Mesothelioma

United States
Gustave Roussy, Cancer Campus, Grand Paris

Completed

A Trial Evaluating the Safety & Efficacy of Intra-Tumoral Ipilimumab in Combination With Intra-venous Nivolumab in Patients With Metastatic Melanoma (NIVIPIT)

Stage III/IV Melanoma

France
Bispebjerg Hospital

Unknown

Laser Immunotherapy With and Without Topical Anti-PD1 in Basal Cell Carcinomas

Immune Response | Immunotherapy | BCC - Basal Cell Carcinoma | Ablative Fractionated Laser

Denmark
NYU Langone Health

Active, not recruiting

Nivolumab Combined With BMS-986253 in HCC Patients

Hepatocellular Carcinoma

United States

Search clinical trials for: GT90001 and Nivolumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Canada

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations